AstraZeneca has signed an AI-led research agreement with China's CSPC Pharmaceutical Group worth up to $5.3 billion, which ...

The deal with China’s CSPC Pharmaceuticals, focused on AI-driven research, aims to advance the discovery and development of ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.

Astra has agreed a deal that could be worth almost £4billion with a Chinese company to use AI in the production of new ...

The collaboration will focus on identifying pre-clinical candidates for high-priority targets, including a small molecule ...

Friday’s deal with fits neatly within AstraZeneca’s business development strategy of upping investments in AI and in China.

British drugmaker AstraZeneca unveiled on Friday an AI-assisted research partnership with Chinese counterpart CSPC ...

CSPC will use its artificial-intelligence-driven, dual-engine efficient drug discovery platform to analyze the binding ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

The collaboration aims to advance the discovery and development of novel oral candidates.

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...